RxDoctor Payments Data

Aditi Bhagat, MD

Family Medicine · Levittown, NYNPI 1598117160

Payments from drug & device makers

$1,445in general payments, 2019–2025

Across 55 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$211
  • Novartis$187
  • Inari Medical, Inc.$155
  • Boehringer Ingelheim$124
  • Amgen$120
  • Novo Nordisk$108
  • plus $540 from 16 others

What the payments were for

  • Food & beverage$1,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,445 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$146,786
Medicare patients
355
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$109,818
EliquisApixaban52$53,272
MounjaroTirzepatide28$37,159
JanuviaSitagliptin Phosphate28$36,493
XareltoRivaroxaban21$34,180
JardianceEmpagliflozin12$18,412
FarxigaDapagliflozin Propanediol12$15,042
TrulicityDulaglutide12$10,619
TradjentaLinagliptin14$9,758
BrilintaTicagrelor12$5,148
Levothyroxine Sodium247$3,860
SynthroidLevothyroxine Sodium58$3,320
Rosuvastatin Calcium163$2,416
Atorvastatin Calcium290$2,327
Olmesartan Medoxomil61$1,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$108$109,81870 claims
PfizerEliquis$90$53,27252 claims
Lilly USA, LLCMounjaro, Trulicity$81$47,77840 claims
MerckJanuvia$211$36,49328 claims
Boehringer IngelheimJardiance, Tradjenta$124$28,17026 claims
AstraZenecaFarxiga, Brilinta$18$20,19024 claims
AbbVieSynthroid$17$3,32058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Levittown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →